Radiopharm Theranostics (RAD), has been granted Human Research Ethics Committee (HREC) approval to commence its First-In-Human Phase 1 study in Australia for the Company's therapy for patients with PDL1 (Programmed death ligand 1)-positive non-small cell lung cancer (NSCLC).

The dose escalation trial of RAD204, which targets PDL1-positive NSCLC, is designed to evaluate the safety and efficacy of this novel radiotherapeutic in eligible individuals with lung cancer. The study will be conducted at Princess Alexandra Hospital in Brisbane, Australia, with the support of leading oncology care provider GenesisCare.

To read more please visit:

RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer

Source: RAD